CTLA4 and melanoma: Because anti-CTLA-4 monotherapy is associated with lower response rates and higher rates of severe Grade 3-4 toxicities than anti-PD-1 monotherapy 2, 3, anti-PD-1 monotherapy has become the preferred immunotherapy therapy in patients with advanced melanoma 4.